UBS AM’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-99,917
| Closed | -$4.74M | – | 3286 |
|
|
2025
Q3 | $4.74M | Sell |
99,917
-61,648
| -38% | -$2.99M | ﹤0.01% | 1394 |
|
|
2025
Q2 | $8.62M | Buy |
161,565
+51,656
| +47% | +$2.35M | ﹤0.01% | 1436 |
|
|
2025
Q1 | $4.45M | Buy |
109,909
+38,458
| +54% | +$1.63M | ﹤0.01% | 1633 |
|
|
2024
Q4 | $1.99M | Buy |
71,451
+11,035
| +18% | +$334K | ﹤0.01% | 2047 |
|
|
2024
Q3 | $1.73M | Sell |
60,416
-5,198
| -8% | -$136K | ﹤0.01% | 2120 |
|
|
2024
Q2 | $1.54M | Buy |
65,614
+19,075
| +41% | +$408K | ﹤0.01% | 2139 |
|
|
2024
Q1 | $1.18M | Hold |
46,539
| – | – | ﹤0.01% | 1929 |
|
|
2023
Q4 | $1.09M | Hold |
46,539
| – | – | ﹤0.01% | 1980 |
|
|
2023
Q3 | $2.35M | Buy |
46,539
+8,449
| +22% | +$393K | ﹤0.01% | 1539 |
|
|
2023
Q2 | $1.46M | Hold |
38,090
| – | – | ﹤0.01% | 1826 |
|
|
2023
Q1 | $1.46M | Buy |
38,090
+2,121
| +6% | +$94.6K | ﹤0.01% | 1826 |
|
|
2022
Q4 | $1.97M | Buy |
35,969
+11,360
| +46% | +$487K | ﹤0.01% | 1532 |
|
|
2022
Q3 | $838K | Sell |
24,609
-9,263
| -27% | -$142K | ﹤0.01% | 2071 |
|
|
2022
Q2 | $320K | Buy |
33,872
+15,232
| +82% | +$159K | ﹤0.01% | 2461 |
|
|
2022
Q1 | $265K | Buy |
+18,640
| New | +$326K | ﹤0.01% | 2625 |
|
|
2021
Q2 | – | Sell |
-7,300
| Closed | -$212K | – | 2752 |
|
|
2021
Q1 | $212K | Sell |
7,300
-1,100
| -13% | -$33.3K | ﹤0.01% | 2559 |
|
|
2020
Q4 | $217K | Hold |
8,400
| – | – | ﹤0.01% | 2481 |
|
|
2020
Q3 | $259K | Buy |
+8,400
| New | +$294K | ﹤0.01% | 2339 |
|
Other funds holding AKRO
UBS AM's AKRO Position: Q4 2025 in Review
UBS AM sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 99,917 shares — an estimated $4.74M sold.
UBS AM first reported a position in AKRO in Q3 2020 and held it in 18 quarters. The position peaked at $8.62M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- UBS AM reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- UBS AM sold 99,917 Akero Therapeutics shares in Q4 2025, an estimated $4.74M.
- UBS AM first reported a position in Akero Therapeutics in Q3 2020 and held it in 18 quarters.
- UBS AM's Akero Therapeutics position peaked at $8.62M in Q2 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on UBS AM's 13F filing for Q4 2025, filed 13 Feb 2026.